D
Celcuity Inc. CELC
$99.74 -$0.18-0.18% NASDAQ
Recommendation
Prev Close
$99.74
Volume
549,573
Avg Vol (90D)
1,037,076
Market Cap
$4.62B
Dividend & Yield
--
52-Week Range
$7.58 - $112.64
P/E (TTM)
--
EPS (TTM)
-$3.67
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Stocks You’ll Wish You Bought Before 2026
12/3/2025 - MarketBeat
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
12/31/2025 - MarketBeat
Celcuity (CELC, $101.55) entered Downtrend as Momentum indicator drops below 0 level on Dec 29, 2025
12/30/2025 - Tickeron - Stocks
Celcuity (CELC, $102.61) Stochastic Oscillator left the oversold zone on December 24, 2025
12/25/2025 - Tickeron - Stocks
Celcuity (CELC, $102.61) entered Uptrend as Momentum indicator ascends above 0 level on Dec 24, 2025
12/25/2025 - Tickeron - Stocks
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
12/24/2025 - Seeking Alpha - Long Ideas
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
12/24/2025 - SeekingAlpha
Celcuity (CELC): Reassessing Valuation After New VIKTORIA-1 Breast Cancer Data Boosts Investor Interest
12/21/2025 - Simply Wall St
Top Biotech Stocks To Add to Your Watchlist - December 20th
12/20/2025 - MarketBeat
Celcuity (CELC, $99.05) entered Downtrend as Momentum indicator drops below 0 level on Dec 17, 2025
12/18/2025 - Tickeron - Stocks
Celcuity (CELC, $99.05) Stochastic Oscillator left the oversold zone on December 17, 2025
12/18/2025 - Tickeron - Stocks
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
12/16/2025 - Zacks Investment Research
Did Gedatolisib's Phase 3 PFS and Tolerability Data Just Shift Celcuity's (CELC) Investment Narrative?
12/15/2025 - Simply Wall St
Celcuity (CELC) Valuation Check After Paradigm-Shifting VIKTORIA-1 Breast Cancer Data Update
12/13/2025 - Simply Wall St
Top Biotech Stocks To Add to Your Watchlist - December 12th
12/13/2025 - MarketBeat
Celcuity (NASDAQ:CELC) Hits New 1-Year High - Should You Buy?
12/13/2025 - MarketBeat
Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Wells Fargo & Company
12/13/2025 - Ticker Report
Eventide Asset Management LLC Buys 123,774 Shares of Celcuity, Inc. $CELC
12/13/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Joint (JYNT)
12/12/2025 - TipRanks Financial Blog
Wells Fargo Initiates Coverage of Celcuity (CELC) with Positive Outlook
12/12/2025 - GuruFocus
Wells Fargo bullish on Celcuity, initiates with an Overweight
12/12/2025 - The Fly
Celcuity initiated with bullish view at Wells Fargo
12/12/2025 - The Fly
Celcuity (NASDAQ:CELC) Director Sells $317,070.00 in Stock
12/12/2025 - Ticker Report
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
12/12/2025 - Zacks Investment Research
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 ...
12/11/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$159.27M
EBIT (TTM)
-$159.42M
Net Income (TTM)
-$162.72M
Balance Sheet
Total Assets (Q)
$476.00M
Total Debt (Q)
$320.35M
Total Liabilities (Q)
$359.04M
Book Value Per Share (Q)
$2.70
Cash Flow
Cash from Operations (TTM)
-$144.65M
Cash from Investing (TTM)
-$129.93M
Cash from Financing (TTM)
$336.23M
Net Change in Cash (TTM)
$61.65M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
End of March (est)
Price History
Loading...
Beta
-0.44
7-Day Total Return
-1.38%
30-Day Total Return
8.89%
60-Day Total Return
102.66%
90-Day Total Return
102.52%
Year to Date Total Return
659.63%
1-Year Total Return
659.63%
2-Year Total Return
574.83%
3-Year Total Return
678.00%
5-Year Total Return
856.28%
52-week Low
Apr 08, 2025 - $7.58
52-week High
Dec 12, 2025 - $112.64
Valuation
Market Cap
$4.62B - Mid Cap
Enterprise Value
$4.48B
Price/Sales (TTM)
--
Price/Book (Q)
36.90
Dividends and Shares
Shares Outstanding
47.59
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.celcuity.com
Phone Number
763 392 0767
Address
16305 36th Avenue North
Minneapolis, MN 55446
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug... more
NASDAQ 12/31/2025 4:00PM Eastern Quotes delayed